Project 3: Impact of the FGF21-Adiponectin-Ceramide Axis on Healthspan Abstract Adipocytes secrete numerous lipid and protein factors with profound effects on systemic energy homeostasis. One such adipokine that we first identified in the early 1990's, adiponectin (previously referred to as Acrp30), has garnered significant attention as a potent mediator of insulin sensitivity and cell survival. FGF21 is another factor released by a number of cell types (including adipocytes) that has beneficial effects on metabolism. In genetically diabetic and diet-induced obese mice, FGF21 lowers blood glucose levels and enhances insulin sensitivity only when adiponectin is functionally present. We have shown that both FGF21 as well as adiponectin lower systemic and tissue levels of ceramides, a class of lipids that has been tightly linked to insulin resistance, inflammation and apoptosis. FGF21 is also a potent secretagogue for adiponectin in adipocytes. This is also in line with two recent papers that argue that the FGF21 receptors, FGFR1 and ?- klotho, exert their primary effects through their presence in adipocytes. Our colleagues Kliewer and Mangesldorf in Project 1 have previously demonstrated that FGF21 overexpressing mice show longer lifespan in mice. Additional clinical data suggests that adiponectin may be a longevity gene. Based on this broad set of preliminary data that argues for the FGF21-adiponectin axis to be a major player in health-span and longevity, we propose the hypothesis that FGF21, via adiponectin, lowers age-related `lipotoxicity' and controls metabolic health- and lifespan by effectively lowering systemic and tissue ceramide levels. We are in a unique position to experimentally test this hypothesis, because the necessary mouse models to address this question have just recently become available. Teaming up with the 3 other laboratories that are part of this PPG, each bringing a unique tool set and expertise to the table, allows us to shed light on this very important axis with major implications for health-span and longevity. Specifically, we will address this topic with 3 distinct Aims.
In Specific Aim 1, we will establish whether adiponectin has an effect on health-span. This has never been tested preclinically. We will systemically analyze thymic lymphopoiesis and assess T cell repertoire diversity (Project 2) and mitochondrial function (Project 4) as a function of age and adiponectin.
In Specific Aim 2, we will determine the contributions of adiponectin on FGF21-mediated healthspan and lifespan. We will examine the effects of the presence and absence of adiponectin on FGF21-mediated benefits on aging in the context of FGF21 transgenic mice.
This aim will be performed in close collaboration with Project 1 and Core B.
In Specific Aim 3, we will evaluate whether FGF21/adiponectin mediated lowering of age-related increase in ceramides controls adipose tissue inflammation and functional decline. We already have generated inducible models of acid ceramidase in adipocytes and hepatocytes that dramatically improve insulin sensitivity. Combined, the proposed studies should shed new insights into the physiology of FGF21/adiponectin mediated aging, and will establish whether these effects are exerted through a lowering of ceramide species.
The role of adipose tissue in systemic energy homeostasis is widely appreciated. It serves as a sink for potentially toxic lipids, but it also engages in an intense crosstalk with other tissues through synthesis and release of protein factors (?adipokines?) and bioactive lipids (?lipokines?). In the proposed studies, we will examine the impact of two critical adipokines, adiponectin and FGF21 on healthspan and lifespan. FGF21 enhances adiponectin levels, and combined, they lower systemic ceramide levels and improve insulin sensitivity. We will examine the relationship of these three components - FGF21/adiponectin/ceramides ? and pursue these studies in the context of healthspan and lifespan with the combined help of all four participating laboratories, taking advantage of tools and insights contributed by each of the participating investigators in their respective areas of expertise, and the Cores.
| Crewe, Clair; Joffin, Nolwenn; Rutkowski, Joseph M et al. (2018) An Endothelial-to-Adipocyte Extracellular Vesicle Axis Governed by Metabolic State. Cell 175:695-708.e13 |
| Song, Parkyong; Zechner, Christoph; Hernandez, Genaro et al. (2018) The Hormone FGF21 Stimulates Water Drinking in Response to Ketogenic Diet and Alcohol. Cell Metab 27:1338-1347.e4 |
| Scherer, Philipp E (2018) The many secret lives of adipocytes: implications for diabetes. Diabetologia : |
| Katafuchi, Takeshi; Holland, William L; Kollipara, Rahul K et al. (2018) PPAR?-K107 SUMOylation regulates insulin sensitivity but not adiposity in mice. Proc Natl Acad Sci U S A 115:12102-12111 |
| Kruglikov, Ilja L; Zhang, Zhuzhen; Scherer, Philipp E (2018) The Role of Immature and Mature Adipocytes in Hair Cycling. Trends Endocrinol Metab : |
| Stoiljkovic, Milan; Kelley, Craig; Horvath, Tamas L et al. (2018) Neurophysiological signals as predictive translational biomarkers for Alzheimer's disease treatment: effects of donepezil on neuronal network oscillations in TgF344-AD rats. Alzheimers Res Ther 10:105 |
| Xia, Jonathan Y; Sun, Kai; Hepler, Chelsea et al. (2018) Acute loss of adipose tissue-derived adiponectin triggers immediate metabolic deterioration in mice. Diabetologia 61:932-941 |
| Kusminski, Christine M; Scherer, Philipp E (2018) New zoning laws enforced by glucagon. Proc Natl Acad Sci U S A 115:4308-4310 |
| Dodd, Garron T; Michael, Natalie J; Lee-Young, Robert S et al. (2018) Insulin regulates POMC neuronal plasticity to control glucose metabolism. Elife 7: |
| Ravussin, Anthony; Youm, Yun-Hee; Sander, Jil et al. (2018) Loss of Nucleobindin-2 Causes Insulin Resistance in Obesity without Impacting Satiety or Adiposity. Cell Rep 24:1085-1092.e6 |
Showing the most recent 10 out of 24 publications
